The Oncologic Drugs Advisory Committee (ODAC) receives requests for technical and clinical evaluation of new drugs by the

U.S. Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food s ...

(FDA). The committee, consisting of members from academic and clinical oncology biostatistics, the general public, and the pharmaceutical industry, makes non-binding recommendations to both the

CDER The Center for Drug Evaluation and Research (CDER, pronounced "see'-der") is a division of the U.S. Food and Drug Administration (FDA) that monitors most drugs as defined in the Food, Drug, and Cosmetic Act. Some biological products are also leg ...

and

CBER The Center for Biologics Evaluation and Research (CBER) is one of six main centers for the U.S. Food and Drug Administration (FDA), which is a part of the U.S. Department of Health and Human Services. The current Director of CBER is Peter Marks ...

divisions of the FDA about the advisability of approving new medications to treat

cancer Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal b ...

References

*Oncologic Drugs Advisory Committee, official webpage: https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/default.htm

External links

*FDA Advisory Committees Calendar (including ODAC): https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm Food and Drug Administration National agencies for drug regulation Regulators of biotechnology products Pharmacy organizations in the United States Cancer organizations based in the United States {{pharma-stub